Overview

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
Phase:
Phase 4
Details
Lead Sponsor:
Melbourne Health
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Posaconazole